Table 5 Univariable and Multiple logistic regression analysis for the association between TyG and Obstructive CVD
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR (99% CI) | P-value | HR (99% CI) | P-value | |
TyG | 1.001(0.927–1.081) | 0.981 | 1.184(0.761–1.842) | 0.454 |
Age(years) | 1.036(1.016–1.056) | < 0.001 | 1.036(0.998–1.075) | 0.064 |
BMI | 0.989(0.937–1.045) | 0.700 | -- | -- |
TC, mmol/L | 0.811(0.674–0.976) | 0.026 | -- | -- |
TG, mmol/L | 0.795(0.641–0.987) | 0.037 | -- | -- |
LDL-C, mmol/L | 0.278(0.871–1.118) | 0.278 | -- | -- |
HDL-C, mmol/L | 0.654(0.380–1.125) | 0.125 | -- | -- |
HbA1c% | 1.296(1.109–1.514) | < 0.001 | 2.686(1.071–6.730) | 0.035 |
Fasting glucose, mmol/L | 0.874(0.720–1.061) | 0.001 | -- | -- |
eGFR-EPI, mL/min/1.73 m2 | 1.009(0.999–1.019) | 0.069 | -- | -- |
Smoke | 1.927(1.155–3.214) | 0.012 | 1.600(0.615–4.164) | 0.336 |
Hypertension | 1.575(0.942–2.635) | 0.084 | -- | -- |
DIabetes | 1.383(0.839–2.281) | 0.203 | -- | -- |
Statins use | 1.753(1.184–2.597) | 0.005 | 1.328(0.457–3.862) | 0.602 |
Ezetimibe use | 4.243(1.500-12.005) | 0.006 | 0.732(0.106–5.035) | 0.751 |